Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Non-Invasive Neuromodulation Device for In-Home Treatment of Overactive Bladder

Award Number: R44AG058272
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2017
PERIOD OF PERFORMANCE END DATE: 04/30/2022

Group Awards By:

View Award Description

A Non-Invasive Neuromodulation Device for In-Home Treatment of Overactive Bladder - Abstract Overactive bladder is a chronic and devastating condition in the aging population. Approximately 33 million people in the United States suffer from overactive bladder (OAB) and associated urinary urge incontinence (UUI), a chronic medical condition that drastically impairs quality of life and results in an annual economic burden of $66 billion. The psychological aspects of this chronic voiding dysfunction are particularly devastating; patients have increased incidences of depression, social isolation and sleep deprivation. Given that the incidence of OAB increases with advancing age, the prevalence of the condition and the total economic burden will continue to rise as the baby boomer population ages. Despite the high social and economic burden, a convenient, safe and effective treatment has yet to be realized. Recently, a minimally invasive neuromodulation device that provides percutaneous tibial nerve stimulation (PTNS) of the afferent sacral nerve, Congentix’s Urgent® PC, has shown clinical success; however, this device requires weekly in-clinic treatments as well as repeated placement of an electrode into the posterior tibial nerve, both of which are cost prohibitive and challenging for patient adherence. Implantable neurostimulators (RENOVA iStim and eCoin™) are also under development, but these devices require a surgical procedure and, accordingly, initial clinical studies have had high complication rates, with a second surgery often required to address these adverse events. To meet the need for a safe, effective, comfortable, and easy-to-use treatment for OAB, TheraNova has developed an inexpensive, convenient device that enables non-invasive tibial nerve stimulation at home. Previously, we demonstrated that subjects treated with this system achieved reductions in the mean number of voids, the mean number of voids with moderate to severe urgency, and the mean number of UUI events. The goals of this Phase II proposal are to determine the effectiveness of our system versus a sham control treatment in a home-use, pivotal clinical study. First, we will conduct a clinical study to identify a well-blinded sham control treatment (Specific Aim 1). Second, we will validate the treatment effectiveness and durability for mitigating urinary urge incontinence compared to the sham control in a pivotal trial (Specific Aim 2). The data obtained will support FDA 510(k) clearance and will allow us to commercialize the system within 3.5 years of the funding of this proposal.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2020	THERANOVA LLC	101 MISSISSIPPI ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	3	10/21/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	THERANOVA LLC	101 MISSISSIPPI ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	3	10/21/2021	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $72,845 )
2021	2021	THERANOVA LLC	101 MISSISSIPPI ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	001	3	1/29/2021	SUPPLEMENT FOR EXPANSION	$0
2021	2021	THERANOVA LLC	101 MISSISSIPPI ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	3	11/13/2020	SUPPLEMENT FOR EXPANSION	$72,845
														Subtotal = $72,845

Issue Date FY: 2020 ( Subtotal = $1,086,149 )
2020	2020	THERANOVA LLC	101 MISSISSIPPI ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	001	3	4/10/2020	NON-COMPETING CONTINUATION	$687,183
2020	2020	THERANOVA LLC	101 MISSISSIPPI ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	003	3	9/2/2020	SUPPLEMENT FOR EXPANSION	$0
2020	2020	THERANOVA LLC	101 MISSISSIPPI ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	002	3	8/26/2020	SUPPLEMENT FOR EXPANSION	$398,966
2020	2019	THERANOVA LLC	101 MISSISSIPPI ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	2	1/24/2020	COMPETING CONTINUATION	$0
														Subtotal = $1,086,149

Issue Date FY: 2019 ( Subtotal = $806,779 )
2019	2019	THERANOVA LLC	101 MISSISSIPPI ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	2	9/22/2019	COMPETING CONTINUATION	$806,779
														Subtotal = $806,779

Grand Total All Awards = $1,965,773

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Non-Invasive Neuromodulation Device for In-Home Treatment of Overactive Bladder

Award Number: R44AG058272

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2017

PERIOD OF PERFORMANCE END DATE: 04/30/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer